Stay updated with breaking news from Extended Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cereno Scientific , a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has been granted approval by the FDA for Expanded Access,...
Operator: Thank you for standing by and welcome to the Q1 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
Company reports on productive interactions with FDA and preparations for launch of omidubicel, if approved, in advance of May 1 PDUFA date Company outlines strategic restructuring, plans to... | March 27, 2023
![Beyond Batten Disease Foundation Announces Agreement with Actelion [...] - Vimarsana News](https://www.cataniaoggi.it/img/logo_social.jpg){kind=logo}
02 marzo 2021 17:14 Fonte: Adnkronos #salute-e-benessere AUSTIN, Texas, March 2, 2021 /PRNewswire/ -- Beyond Batten Disease Foundation (BBDF) is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® (miglustat) for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease (CLN3). Janssen will provide drug supply for the clinical trials and Extended Access Program, and right of reference to data within the Zavesca New Drug Application (NDA) to sup...